This is consistent with prior evidence that CEA has low sensitivity in stage I-II colorectal cancer and is more useful for prognosis and surveillance in advanced disease, while CA 19-9 lacks specificity and is not recommended for screening or diagnosis of colorectal cancer [11-13]. The gene discussed is CEACAM5; the disease is colorectal cancer.